Share Name Share Symbol Market Type Share ISIN Share Description
Verseon Corporation LSE:VERS London Ordinary Share COM USD0.001 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 42.00p 40.00p 44.00p 42.00p 42.00p 42.00p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -16.9 -11.0 - 67

Verseon Corporation Additional Listing & Total Voting Rights

25/06/2019 7:01am

UK Regulatory (RNS & others)


Verseon (LSE:VERS)
Historical Stock Chart

1 Month : From Jun 2019 to Jul 2019

Click Here for more Verseon Charts.

TIDMVERS

RNS Number : 3082D

Verseon Corporation

25 June 2019

June 25, 2019

Verseon Corporation

("Verseon" or the "Company")

Additional Listing & Total Voting Rights

Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 158,042 common shares of par value $0.001 each ("Common Shares") to be admitted to trading on AIM pursuant to option exercise of 5,542 common shares as well as regularly scheduled vesting of restricted stock units and restricted stock awards of 152,500 common shares (the "Issuance").

The 158,042 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on June 28, 2019 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 159,729,429 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 159,686,512. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information please contact:

 
Verseon Corporation                             www.verseon.com 
                                                   +1 (510) 225 
Sebastian Wykeham / Tina Schlafly                          9000 
 
Arden Partners (NOMAD and Joint Broker) 
Ruari McGirr / Ciaran Walsh / Dan Gee-Summons 
 (Corporate Finance) /                          +44 (0) 20 7614 
 Fraser Marshall (Equity Sales)                            5900 
 
Cantor Fitzgerald Europe (Joint Broker) 
                                                +44 (0) 20 7894 
Phil Davies                                                7000 
 

For financial and business media enquiries, please contact

 
Buchanan Communications Ltd (PR Advisors) 
Henry Harrison-Topham / Jamie Hooper   +44 (0) 20 7466 5000 
 

For trade and pharma media enquiries, please contact

 
Vane Percy & Roberts 
Simon Vane Percy   +44 (0) 1737 821 89 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEALKSAEENEEF

(END) Dow Jones Newswires

June 25, 2019 02:01 ET (06:01 GMT)

1 Year Verseon Chart

1 Year Verseon Chart

1 Month Verseon Chart

1 Month Verseon Chart
Your Recent History
LSE
VERS
Verseon
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190719 18:55:39